11
Novo Nordisk Drops ZEUS Trial Update: Major Implications for ASCVD & CKD
Novo Nordisk’s ZEUS Trial: What Happened When They Tried to Fight Heart Disease by Calming Inflammation?
Quick Takeaway: Novo Nordisk tested a new medicine called ziltivekimab to see if lowering inflammation could prevent heart attacks and strokes in high-risk patients. The medicine successfully lowered inflammation markers, but it did not reduce major heart events compared to a placebo. Two other studies are still ongoing.
What Is This All About?
On July 31, 2026, Novo Nordisk (a global healthcare company based in Denmark) announced the results of a major clinical trial called ZEUS.
Scientists have long known that inflammation plays a big role in heart disease. The idea behind ZEUS was simple but bold:
If we calm down inflammation in the body, can we prevent heart attacks, strokes, and cardiovascular death?
The answer from this trial? Not in this group of patients.
The Medicine: Ziltivekimab (The "Inflammation Calmer")
What is it?
Ziltivekimab is an investigational medicine — meaning it’s not approved for use yet. It’s a monoclonal antibody (a lab-made protein that acts like a guided missile in your immune system).
How does it work?
- It targets IL-6 (interleukin-6), a protein that signals your body to create inflammation.
- By blocking IL-6, ziltivekimab turns down the "inflammation alarm."
- Think of it like a firefighter that puts out a smoldering fire inside your blood vessels.
What was it being tested for?
- Atherosclerotic cardiovascular disease (ASCVD) — plaque buildup in arteries
- Chronic kidney disease (CKD)
- High inflammation (measured by hsCRP ≥ 2 mg/L)
The ZEUS Trial: How They Tested It
| Detail | Description |
|---|---|
| Trial Name | ZEUS (cardiovascular outcomes trial) |
| Participants | Over 6,300 people with ASCVD, CKD, and high inflammation |
| Design | Double-blind, placebo-controlled (gold standard) |
| Treatment | Once-monthly ziltivekimab 15 mg injection vs. placebo |
| Duration | Event-driven (ran until enough heart events occurred) |
| Main Goal (Primary Endpoint) | Time to first MACE — Major Adverse Cardiovascular Events: • Cardiovascular death • Non-fatal heart attack • Non-fatal stroke |
ELI5: "Double-blind, placebo-controlled"
Neither the patients nor the doctors knew who got the real drug and who got a fake (placebo) injection. This prevents bias — like a fair taste test where no one knows which soda is which.
What They Found: The Big Results
The Primary Result: No Benefit on MACE
- Hazard Ratio (HR): 0.99
- 95% Confidence Interval: 0.88 to 1.11
What does this mean?
A hazard ratio of 1.0 means no difference between drug and placebo.
The confidence interval includes 1.0 → statistically no effect.
The Drug Did Work Biologically
- Free IL-6 levels dropped → Target hit!
- hsCRP (inflammation marker) dropped → Inflammation calmed down!
But… That Didn’t Translate to Fewer Heart Events
Key Quote from Martin Holst Lange (Novo Nordisk R&D Chief):
"Although ziltivekimab produced the expected biological effect, this did not result in MACE benefits in this population."
Safety: What About Side Effects?
| Safety Measure | Ziltivekimab | Placebo |
|---|---|---|
| Overall adverse events | Similar | Similar |
| Serious adverse events | Similar | Similar |
| Serious infections | Higher | Lower |
| All-cause mortality | No difference | No difference |
Important: Blocking IL-6 weakens part of the immune system → more serious infections. This is a known risk with this type of drug.
What This Means for the Future
Two Other Trials Are Still Running
| Trial | Population | Expected Results |
|---|---|---|
| HERMES | Heart failure (HFpEF) | First half of 2027 |
| ARTEMIS | After acute heart attack (MI) | First half of 2027 |
Why keep going?
Inflammation may play different roles in different heart conditions. What fails in one group might work in another.
Scientific Value
- This trial proves that lowering IL-6/hsCRP alone isn’t enough to prevent MACE in this population.
- It gives researchers critical clues for future drug development.
Money Matters: Financial Impact
For Investors & Curious Minds:
- No change to Novo Nordisk’s 2026 adjusted operating profit outlook
- But: A non-cash impairment charge in Q3 2026 (accounting write-down, not cash leaving the bank)
What Happens Next?
- Full results → Presented at a scientific meeting in 2026
- HERMES & ARTEMIS → Continue as planned, read out H1 2027
- Novo Nordisk → Stays committed to cardiovascular research
- Patients → Still need better treatments for high-risk heart/kidney disease
IMPORTANT POINT
Lowering inflammation markers ≠ preventing heart attacks
This trial teaches us that biology is complex. Just because a drug hits its target doesn’t mean it changes the disease outcome. Science advances by learning what doesn’t work, too.
Summary
| Question | Answer |
|---|---|
| What was tested? | Ziltivekimab (anti-IL-6 antibody) vs. placebo |
| In whom? | 6,300+ people with heart disease, kidney disease, and high inflammation |
| Did it lower inflammation? | Yes — IL-6 and hsCRP dropped as expected |
| Did it prevent heart attacks/strokes/death? | No — HR 0.99 (no difference) |
| Was it safe? | Mostly, but more serious infections |
| What’s next? | Two more trials (HERMES, ARTEMIS) continue; results in 2027 |
| Financial hit? | Non-cash charge in Q3 2026; 2026 profit outlook unchanged |
FAQ
1. What is IL-6, and why block it?
IL-6 is a signaling protein that tells your body to ramp up inflammation. In heart disease, chronic inflammation damages blood vessels. Blocking IL-6 should help — but this trial shows it’s not that simple.
2. What is hsCRP?
High-sensitivity C-reactive protein — a blood test that measures low-level inflammation. Higher levels = higher heart risk. Ziltivekimab lowered it, but that didn’t save lives.
3. Does this mean anti-inflammatory drugs don’t work for heart disease?
Not necessarily. Other drugs (like colchicine) have shown benefit. It depends on which inflammation pathway you block, in whom, and when.
4. Why are HERMES and ARTEMIS still running?
Heart failure and post-heart attack patients may have different inflammation biology. The drug might work there — or it might not. Science needs to test each group separately.
5. Should patients be worried?
No one was harmed in a way that changes standard care. The drug isn’t approved. If you’re in one of the ongoing trials, your doctor will keep you informed.
Source: Novo Nordisk Company Announcement No 45 / 2026 (31 July 2026)
Full results to be presented at a scientific meeting in 2026.
